Kodiak Sciences Q1 2026 net loss of $58.2 million, or $0.94 per share
Kodiak Sciences reported a net loss of $58.2 million, or $0.94 per share, for the quarter ended March 31, 2026, compared with a net loss of $57.5 million, or $1.09 per share, a year earlier. The dollar loss widened slightly as research and development spending rose, while general and administrative expenses fell, and cash and cash equivalents declined to $169.5 million; the company says this cash will support operations into 2027.
Key points
- Net loss was $58.2 million, or $0.94 per share, versus $57.5 million, or $1.09 per share, in the first quarter of 2025.
- R&D expenses rose to $48.5 million from $43.6 million, driven by PEAK/PINNACLE and DAYBREAK clinical activity.
- G&A expenses fell to $11.2 million from $15.4 million, helped by sublease income.
- Cash and cash equivalents were $169.5 million at March 31, 2026, down from $209.9 million at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.